Sugi Predict

Sugi Predict / Compounds / Tingenone

Tingenone

Tingenone

SCHEMBL20957664

CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@]2(C)[C@@H]3C[C@@H](C)C(=O)C[C@]3(C)CC[C@@]12C

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.66
▸ CCR6 P51684 1/20 0.66
▸ PAX8 Q06710 1/20 0.66
▸ TLR9 Q9NR96 1/20 0.66
▸ NR4A1 P22736 7/20 0.65
▸ PTPN1 P18031 1/20 0.64
▸ CASP1 P29466 1/20 0.64
▸ ABHD6 Q9BV23 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.64
▸ TP53 P04637 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ HPGD P15428 1/20 0.64
▸ ALOX15 P16050 1/20 0.64
▸ ALOX12 P18054 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ TERT O14746 6/20 0.63
▸ HSP90AB1 P08238 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tingenone SCHEMBL20980043 1.00 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenone SCHEMBL17064 1.00 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL16338706 0.86 CASP3 (0.61) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL20028 0.86 HSP90AA1 (0.69) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL29475985 0.86 HSP90AA1 (0.69) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL30688055 0.84 HSP90AA1 (0.67) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781832 0.82 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL17328989 0.82 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenin B SCHEMBL20957640 0.82 HSP90AA1 (0.60) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenin B SCHEMBL19604972 0.82 HSP90AA1 (0.60) HSP90AA1CCR6PAX8TLR9NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4479072-B1 COMPOSITION COMPRISING A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING ACNE OF NON-LESIONAL AREAS OF ACNEIC SKIN PIERRE FABRE DERMO COSMETIQUE (FR) 2026-03-04 — — EP claimed
EP-4304622-B1 COMBINATION OF A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING C. ACNES-INDUCED INFLAMMATION PIERRE FABRE DERMO COSMETIQUE (FR) 2026-01-14 — — EP claimed
EP-4479072-A1 COMPOSITION COMPRISING A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFODII EXTRACT FOR CONTROLLING ACNE OF NON-LESIONAL AREAS OF ACNEIC SKIN Pierre Fabre Dermo-Cosmétique (FR) 2024-12-25 — — EP claimed
US-20240165185-A1 COMBINATION OF A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR COMBATING C. ACNES-INDUCED INFLAMMATION PIERRE FABRE DERMO-COSMETIQUE (FR) 2024-05-23 — — US claimed
EP-3965790-B1 PENTACYCLIC TRITERPENES IN THE TREATMENT OF VITILIGO FABRE PIERRE DERMO COSMETIQUE (FR) 2024-05-01 — — EP claimed
EP-4304622-A1 COMBINATION OF A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING C. ACNES-INDUCED INFLAMMATION Pierre Fabre Dermo-Cosmétique (FR) 2024-01-17 — — EP claimed
EP-3710011-B1 PENTACYCLIC TRITERPENES FOR THE TREATMENT OF AN ORAL DISEASE PF MEDICAMENT (FR) 2023-11-29 — — EP claimed
WO-2023156745-A1 COMPOSITION COMPRISING A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING ACNE OF NON-LESIONAL AREAS OF ACNEIC SKIN PIERRE FABRE DERMO-COSMETIQUE (FR) 2023-08-24 — — WO claimed
WO-2022189758-A1 COMBINATION OF A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING C. ACNES-INDUCED INFLAMMATION PIERRE FABRE DERMO-COSMETIQUE (FR) 2022-09-15 — — WO claimed
EP-3875078-A1 COMPOUNDS FOR THE TREATMENT OF COVID-19 Dompe' Farmaceutici S.P.A. (IT) 2021-09-08 — — EP claimed
CN-102174105-A Antibodies directed to her-3 and uses thereof U3 PHARMA AG 2011-09-07 — — CN claimed
CN-102076717-A Crosslinking agents and their use IMMUNOGEN INC 2011-05-25 — — CN claimed
CN-101965366-A The immunoconjugates of target CD138 and application thereof BIOTEST AG 2011-02-02 — — CN claimed
CN-101945892-A Methods and reagents for improved targeting of CD138 expressing tumor cells BIOTEST AG 2011-01-12 — — CN claimed
CN-101622276-A Antagonistic antibodies against EPHA2 for the treatment of cancer SANOFI AVENTIS 2010-01-06 — — CN claimed
CN-101616933-A Novel anti-CD 38 antibodies for the treatment of cancer SANOFI AVENTIS 2009-12-30 — — CN claimed
CN-101365723-A Antibodies to HER-3 and uses thereof U3 PHARMA AG (DE) 2009-02-11 — — CN claimed
CN-101287841-A Anti-alphavβ6Antibodies and uses thereof BIOGEN IDEC MA (US) 2008-10-15 — — CN claimed
CN-1922199-A CA6 antigen-specific cytotoxic conjugates and methods of use thereof IMMUNOGEN INC (US) 2007-02-28 — — CN claimed
CN-1571782-A Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORP (US) 2005-01-26 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240165185-A1 COMBINATION OF A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR COMBATING C. ACNES-INDUCED INFLAMMATION HMGB2, NFKBIA, CUTA HSP90AA1 1246/4885CCR6 1798/4885PAX8 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.